Hospital Mater Dei (BSP:MATD3) Research & Development: R$0 Mil (TTM As of Mar. 2026)


BSP:MATD3 Hospital Mater Dei SA BSP:MATD3
83 GF Score
Price R$4.86
GF Value R$5.85
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Hospital Mater Dei Research & Development?

Hospital Mater Dei BSP:MATD3 +3.18% 83 Research & Development is R$0 Mil as of Mar. 2026. GuruFocus rates BSP:MATD3 with a GF Score™ of 83/100 and a GF Value™ of R$5.85 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hospital Mater Dei's Research & Development for the three months ended in Mar. 2026 was R$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was R$0 Mil.

Hospital Mater Dei  (BSP:MATD3) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hospital Mater Dei Research & Development Related Terms

Hospital Mater Dei Research & Development Historical Data

* Premium members only.

The historical data trend for Hospital Mater Dei's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hospital Mater Dei Research & Development Chart

Hospital Mater Dei Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hospital Mater Dei Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:MATD3
83GF Score
Hospital Mater Dei SA BSP:MATD3
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hospital Mater Dei Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R$0 Mil mean?
Hospital Mater Dei (BSP:MATD3) has a Research & Development of R$0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Hospital Mater Dei and its competitors.
Is Hospital Mater Dei's Research & Development too high?
Hospital Mater Dei's current Research & Development is R$0 Mil. Overall, Hospital Mater Dei has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hospital Mater Dei's Research & Development compare to HCA and THC?
Hospital Mater Dei's Research & Development of R$0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hospital Mater Dei and its competitors. Hospital Mater Dei's current Research & Development is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hospital Mater Dei stock overvalued right now?
Based on GuruFocus' analysis, Hospital Mater Dei (BSP:MATD3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$5.85, compared to a current price of R$4.86 — trading 16.9% below its estimated fair value. The current Research & Development is R$0 Mil. Hospital Mater Dei's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hospital Mater Dei (BSP:MATD3), the current Research & Development is R$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hospital Mater Dei (BSP:MATD3) Overvalued in 2026?

Based on GuruFocus' analysis, Hospital Mater Dei stock appears to be undervalued. The current stock price of R$4.86 is trading 16.9% below its estimated GF Value™ of R$5.85. GuruFocus considers Hospital Mater Dei to be Modestly Undervalued.

Key valuation signals for BSP:MATD3:

  • Research & Development: R$0 Mil
  • GF Value™: R$5.85 vs. price of R$4.86 (16.9% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the BSP:MATD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hospital Mater Dei Business Description

Address Rua Mato Grosso, No. 1, 100, Bairro Santo Agostinho, Belo Horizonte, MG, BRA, 30.190-081
Hospital Mater Dei SA is an integrated healthcare ecosystem that provides hospital and oncological services. The company provides a wide range of healthcare services, including hospitalizations, surgeries, oncology treatments, medical appointments, and diagnostic exams.
83GF Score

Get the complete analysis for BSP:MATD3

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$4.86
Price
R$5.85
GF Value